Task: gap016 | Last Updated: 2026-03-24 | Kind: gap-analysis | Total Gaps Identified: 7
Recent advances in multi-modal immune profiling have improved ALS patient stratification:
New understanding of the bidirectional communication between CNS and peripheral immune system:
Immune biomarkers now integrated as exploratory endpoints in multiple Phase 2/3 trials:
Emerging immunomodulatory approaches in clinical development:
This knowledge gap page addresses the critical question: How should peripheral and central nervous system (CNS) immune signatures be incorporated into ALS clinical trial stratification? This gap was identified in the ALS Knowledge Gaps Ranked List with a score of 29, reflecting its high impact on clinical trial design and the current lack of consensus on immune-based patient stratification approaches. [1]
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of upper and lower motor neurons. Despite extensive research, over 30 clinical trials have failed to demonstrate efficacy, raising critical questions about patient stratification. The immune system plays a dual role in ALS pathogenesis—contributing to disease progression through neuroinflammation while also potentially providing protective responses. [2]
CSF provides direct access to the CNS immune environment. Key peripheral immune biomarkers relevant to ALS trial stratification include: [3]
| Biomarker | Source | Clinical Relevance |
|-----------|--------|-------------------| Neurofilament light chain (NfL) | CSF, plasma | Disease progression marker, cross-links to ALS Biomarkers and Disease Monitoring | [4]
| Chitinase-3-like protein 1 (YKL-40) | CSF | Microglial activation, correlates with disease progression | [5]
| TGF-β1 | CSF | Anti-inflammatory response, predictive of progression rate | [6]
| IL-6, IL-8, TNF-α | CSF, plasma | Pro-inflammatory cytokines, baseline levels predict rapid progression |
| CSF/serum albumin ratio | CSF | Blood-brain barrier integrity |
Peripheral blood offers repeated sampling advantages for clinical trials:
Microglia are the resident immune cells of the CNS and play a central role in ALS pathogenesis. Key considerations for trial stratification include:
Astrocytes contribute to ALS progression through both protective and toxic mechanisms:
Existing trial stratification relies primarily on:
| Approach | Biomarkers | Current Evidence Level |
|---|---|---|
| Progression rate-based | NfL, IL-6, YKL-40 | Moderate |
| Immune phenotype clustering | Peripheral immune cell subsets | Preliminary |
| Baseline inflammation status | CRP, ESR, cytokine panels | Limited |
| BBB permeability | CSF/serum albumin ratio | Exploratory |
A comprehensive immune stratification framework would integrate:
Baseline immune profiling can identify patient subgroups with distinct disease mechanisms:
Dynamic immune changes during trials can reveal:
While specific 2025-2026 papers were not available at the time of writing, key recent developments include:
Current state: This gap represents an active area of research with no established standard of care for immune-based stratification.
Key unanswered questions:
Benatar M, et al. ALS knowledge gaps: prioritizing research opportunities. 2023. ↩︎
Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2023. ↩︎
Olsson B, et al. CSF biomarkers in ALS: a systematic review. 2023. ↩︎
Thonhoff JR, et al. Updated consensus on ALS clinical trial design and endpoints. 2024. ↩︎
Beers DR, et al. ALS immune modulation: past, present, and future. 2023. ↩︎
Tam OH, et al. Postmortem cortex from ALS patients reveals microglia alterations. 2023. ↩︎